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Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system, in which
both cellular and humoral immune responses are involved. The disease is clinically heterogeneous with some patients displaying
pure motor form and others also showing a variable degree of sensory dysfunction; disease evolution may also differ from patient
to patient, since monophasic, progressive, and relapsing forms are reported. Underlying such clinical variability there is probably
a broad spectrum of molecular dysfunctions that are and will be the target of therapeutic strategies. In this review we first explore
the biological bases of current treatments and subsequently we focus on the practical management that must also take into account
pharmacoeconomic issues.
1. Introduction
Chronic inflammatory demyelinating polyneuropathy
(CIDP) is a peripheral nervous system disease that is clini-
cally characterized by symmetrical,proximal,and distal weak-
ness with altered sensation and hyporeflexia or areflexia [1].
Clinical course can be either relapsing remitting (RR),
chronic progressive (CP), or monophasic [2]. In rare cases,
CIDP displays acute onset and fast deterioration in the early
phases, followed by chronic progression. This variant of
CIDP, defined as “acute onset CIDP,” is difficult to distin-
guish from Guillain-Barre´ syndrome (GBS) in early disease
stages [3]. Epidemiological studies on CIDP report an inci-
dence in Northern Italy around 0.6 cases per 100.000 [4].
Nevertheless, it is probable that the real incidence of CIDP
is largely underestimated, due to the variety of clinical pres-
entations and the absence of proper diagnostic markers. For
this reason, a diagnosis of CIPD must be taken into consid-
eration while examining any polyneuropathy of unknown
cause.
CIDP is an autoimmune disorder, as demonstrated by a
great deal of evidence [5], such as the finding of inflammation
at the site of the lesion [6], response to immunomodulatory
treatment [7], and possibly the presence of autoantibodies
against myelin antigens [8].
Long-term prognosis of CIDP has been correlated to age
at onset, response to treatment, and time from onset to the
beginning of treatment: young patients with acute onset are
more likely to respond to treatment than elderly ones and
proximal impairment has been linked to a better prognosis
than distal weakness [9, 10]. The main negative prognostic
factors of CIDP are progressive course and axonal degener-
ation [11].
CIDP and multiple sclerosis (MS) display similarities in
clinical course and pathogenesis and there are reports on
cooccurrence of these two demyelinating disorders [12], but
no definite conclusion whether such event was coincidental
or due to common mechanisms has been reached.
Peripheral nerve injury results from a synergistic inter-
action of cell-mediated and humoral immune responses
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directed against peripheral nerve antigens that have not been
completely characterized [13].
From laboratory experiments we know that the key
players in the pathogenesis of the disease appear to be T cells,
especially T helper 1 (Th1) and T helper 17 (Th17) on one side
and T regulatory (T reg) on the other [14]. A relevant con-
tribution is also ascribed to the macrophagic component,
cytokines, and complement activation [15–17].
CIDP is defined by a slow clinical deterioration that
reaches its maximum after more than 8 weeks, differently
from GBS, which is an acute and self-limiting disease That
aside, there are many similarities between these two con-
ditions, which may even be variants of the same disease
spectrum,withCIDPbeing the result of prolonged survival of
activated T cells, not undergoing apoptosis due to a defective
Fas pathway function [18–20], and GBS characterized by a
self-limitation likely related to a preserved function of such
apoptotic mechanism. In line with this concept, the finding
that corticosteroids are effective in CIDP and not in GBS
would be related to the known effect of these drugs in restor-
ing T cell apoptosis.
Since inflammation is the core of the disease, it is not
surprising that immunomodulatory treatments have a pos-
itive effect [21]. Nevertheless, it is not yet possible to predict
disease progression on the basis of biological markers [22, 23]
because it is likely that under the general definition of “CIDP”
a broad spectrum of different forms is included [24].
In the following sections we will first discuss the bio-
logical basis for the use of immunomodulatory treatments
in CIDP and subsequently illustrate our current strategy for
choosing the best treatment option in everyday practice.
2. Biological Activity of Available Treatments
Currently available treatments for CIDP are corticosteroids,
immune globulin, plasma exchange (PE), and chronic
immunosuppressive agents [21, 25].
2.1. Steroids. Since the first report [26] of their use in CIDP in
1958, steroids have been considered a first-line therapy in
CIDP. Nonetheless, their mechanism of action in patients
with CIDP is not completely elucidated.
Many effects are mediated by intracellular receptors that
modulate the expression of targeted genes [27]. The result
of gene modulation is a pleiotropic anti-inflammatory effect
mainly related to modulation of cytokines and to facilitation
of apoptosis of T cells directed against the peripheral nerves
[28, 29], as proved in animal models [30, 31] or in multiple
sclerosis in humans [32]. During high-dose pulse therapies
additional effects could occur, such as interferencewith intra-
cellular signal transduction and interaction with activation of
membrane-associated proteins.
A possible explanation for the variability in the clinical
effect of glucocorticoids among patients and in the same
patient, according to the stage of the disease, is alternative
splicing. The alpha isoform of the glucocorticoid receptor
(GR𝛼) is a ligand-activated transcription factor. Alternative
splicing of the glucocorticoid-receptor gene results in the
expression of a GR𝛽 isoform that exhibits negative activity
[33].
A “resistant state” to steroids—that is, a reduced response
to glucocorticoids or the need to increase the dose—has been
described in many autoimmune conditions [34] and seems
to be induced by proinflammatory cytokines [35], increased
GR𝛽 expression, or decreased glucocorticoid receptor bind-
ing. This state of glucocorticoid resistance could be posi-
tively influenced by concomitant treatment with intravenous
immune globulin (IVIg) [36] with mechanisms that are still
unclear but may include suppression of proinflammatory
cytokines [37].
2.2. Intravenous Immune Globulin (IVIg). Thenotion that the
effect of intravenously administered immune globulin (IVIg)
is not limited to antibody replacement is well established.
Since the first demonstrations at the beginning of the 80s [38],
it has become clear that IVIg plays a role in immunomod-
ulation and has anti-inflammatory properties. However, the
anti-inflammatory activity of IVIg is still to be understood
and cannot be attributed to one specific mechanism of action
but rather to a variety of different ones, acting at different lev-
els and involving both innate and adaptive immune systems
[39, 40]. Specifically, anti-inflammatory activities are seen
when IVIg is administered at relatively high doses compared
to those used for antibody replacement. On the contrary, low
doses of IVIg seem to carry out an opposite proinflammatory
activity possibly through the interaction with complement
and activating receptors for the crystallizable fragment por-
tion of IgG (Fc𝛾Rs) [39]. IVIg is a preparation of human
polyclonal IgG obtained from plasma of several thousands
of healthy donors [41], but it also contains traces of IgA and
soluble molecules among which are cytokines, chemokines,
soluble cytokine receptors, and receptor antagonists [39, 40].
Indeed the anti-inflammatory activity of IVIg can be related
to the presence in the preparation of antibodies directed
against serum proinflammatory molecules. However, IVIg
seems also to act by modulating responsiveness to glucocor-
ticoids, enhancing their anti-inflammatory effect [36].
IVIg contains antibodies with different specificities, but
every antibody has the same structure: a variable portion
called antigen-binding fragment (Fab) and a fixed fragment
named crystallizable fragment (Fc) and both have been asso-
ciated, in different ways, with anti-inflammatory activities
[41, 42]. Some of the Fab-mediated activities may include
neutralization of autoantibodies, cytokines, and activated
complement components, anti-idiotype activity directed
against autoreactive lymphocyte clones, modulation of cell
migration, targeting of specific immune cell-surface recep-
tors, andmodulation of dendritic cells function. Fc-mediated
activities instead may include blockade of the neonatal Fc
receptor (FcRn) and activating of Fc𝛾R receptors on macro-
phages and other immune effector cells, upregulation of
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inhibitory receptor Fc𝛾RIIB, and immunomodulation by sia-
lylated IgG [43–45].
A further role of IgGmay be related to a reduction of com-
plement uptake as they can bind to complement fragments
such as C3, C4b, and C5 preventing tissue damage [46]. FcRn
is found in many tissues and its activity increases the half-
life of circulating IgG, as it normally binds to the Fc fragment
and prevents IgG catabolism. High doses of IVIg may lead to
saturation of FcRn with a consequent reduction of the half-
life of autoantibodies [47]. However, this receptor displays
particular affinity for deglycosylated IgG only and this aspect,
which will be later discussed, tends to rule out this hypothesis
[39]. Activating Fc𝛾R receptors also appear to be involved, as
they play a key role in the triggering of effector functions in all
myeloid cells. IgG in the preparation of immune globulinmay
bind to activating Fc𝛾Rs in the form of immune complexes
thus blocking the interaction between autoantibodies and
antigens. It has also been put into evidence that IgG2a and
IgG2b subclasses display a greater capacity to initiate effector
responses and this can be correlated to their higher affinity
for activating Fc𝛾Rs [39, 48].
Moreover IVIg is thought to be able to induce an upreg-
ulation of inhibitory Fc𝛾RIIB receptor on effector cells whose
function is to balance the activity of activating Fc𝛾Rs, dis-
missing inflammatory response by delivering inhibitory sig-
nals [48, 49]. This theory is supported by several studies,
including one conducted on patients affected by CIDP [50].
Another important aspect of IgG function is the role of glyco-
sylation in the interaction with Fc𝛾R receptors [51]. In detail,
it seems that deglycosylated IgG fails to bind to such receptors
[52]. Moreover, it appears that only a small percentage of
glycosylated IVIg with 𝛼-2,6 sialic acid linkages on Fc-linked
glycans is able to exert anti-inflammatory functions [53, 54]
and this could explain why high doses of IVIg are needed to
observe anti-inflammatory effects [47].
It has been suggested that sialylated Fc fragmentsmay not
directly interact with Fc𝛾Rs on effector cells, as they show
reduced affinity, but that they may modulate inflammatory
activity by binding to SIGN-R1 (ICAM-3 adhesion molecule)
expressed on regulatory macrophages leading to the release
of soluble mediators. These mediators would then bind to
effector macrophages increasing the expression of inhibitory
Fc𝛾RIIB which would eventually outcompete activating
Fc𝛾Rs, increasing the number of immune complexes needed
to trigger an inflammatory response [39, 54]. Immunomod-
ulation by glycosylation leads to further considerations on
the complex environmental regulation of immune responses
andweakens those hypotheses based on simple IgG-Fc𝛾R and
IgG-FcRn interactions. However many of these considera-
tions have been derived from studies on animal models and
must still be validated for humans. In spite of the fragmentary
understanding of IVIg anti-inflammatory activity, immune
globulin is successfully used in several autoimmune and
inflammatory conditions including CIDP [55]. As already
observed for steroids, response to treatment is often variable
and this may be linked to genetic differences in immune
system regulation [56] as well as glycosylation patterns in
IVIg preparations.
2.3. Plasma Exchange (PE). There are two main techniques
of standard therapeutic plasmapheresis (or plasma exchange,
PE): on-line plasma separation by a cell separator (centrifuge)
or by a plasma separator (i.e., membrane filtration). A
standard PE protocol for neuromuscular disorders employs
4 to 5 exchanges of 1 or 1.5 plasma volumes over one week
or longer (until the patient shows satisfactory improvement)
[57].
The aim of this treatment is the rapid removal of cir-
culating autoantibodies, cytokines, immune complexes, and
immune cells [58] and therefore PE is used in neuroim-
munological antibody-mediated diseases [59] (e.g., myasthe-
nia gravis) to achieve fast immunosuppression. However,
the duration of these effects is limited in time because of
resynthesis (or even rebound production) of the respective
autoantibodies and therefore PE is combined with immuno-
suppressive medication in chronic diseases.
PE is traditionally used in acute forms of dysimmune
peripheral neuropathies such as GBS, but also patients with
chronic disease such as CIDPmay respond to PE in the short
term, usually for 2–4 weeks [60].
Although there is now no age limit for this treatment,
several possible complications, such as cardiovascular sys-
temic reactions, electrolyte disturbances, sepsis, thrombosis
and thrombophlebitis, pulmonary embolism, and subacute
bacterial endocarditis, limit its chronic use in elderly patients
or in patients with multiorgan disease.
2.4. Immunosuppressive Drugs. Azathioprine (AZA) is an
antimetabolite drug that interferes with the purine pathway
and therefore with DNA synthesis in cell division; it causes
inhibition of proliferating lymphocytes and is often used as
steroid-sparing agent.
Methotrexate is another antimetabolite interfering with
the synthesis of DNA and RNA and is commonly used in
autoimmune diseases (e.g., rheumatoid arthritis).
Ciclosporin A inhibits the proliferation of T cells; its
action seems to be much faster than the one of azathioprine.
Mycophenolate mofetil belongs to the antimetabolite
group and is a prodrug; it inhibits the proliferation of T and
B lymphocytes and is generally well tolerated and relatively
safe to use, although side effects include mild bone marrow
suppression.
Cyclophosphamide is an alkylating agent that can be
given orally or by intravenous injection to deplete T and
B lymphocytes. Neutropenic infections and transient renal
insufficiency as well as other mild adverse effects have
been reported, but the most common adverse effects are
hemorrhagic cystitis, stomatitis, leukopenia, thrombocytope-
nia, malignancy, and cardiomyopathy. Therefore, cyclophos-
phamide should only be considered for patients with a severe
form of CIDP who have been refractory to other treatments.
Rituximab is a chimeric (mouse/human) monoclonal
antibody directed against CD20+ B lymphocytes. It is com-
monly used in lymphoma and has been tried on a small series
of patients with paraproteinaemic demyelinating neuropathy,
with modest benefit in selected patients.
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3. Criteria of Treatment Choice in
the Era of Pharmacoeconomy
Treatment choice will depend on several variables such
as initial disease severity, age, general health status, and
potential contraindications [61]. The recent economic crisis
is opening remarkable questions about the sustainability of
expensive drugs such as IVIg in Western countries and some
national audits [62] or studies [63–65] have been already
performed or are still ongoing (e.g., the prospective observa-
tional study “TEPORE” inNorthern Italy) to clarify this issue.
The treatment with immune globulin is highly expensive,
especially for chronic patients, and there are concerns about
future supplies because the pool of donors is decreasing and
there is the need to improve microbiological screening of
plasma donors.
Subcutaneous formulation of immune globulin is now
available and offers an alternative to intravenous infusions,
especially for patients in working age [66].
Patients with pure motor CIDP should be treated with
IVIg, since deterioration has been reported with steroids, as
in MMN [67].
If a patient has only mild symptoms, a nerve biopsy could
help to confirm the diagnosis and establish the need for inter-
vention if axonal degeneration has already occurred. Mild
symptomatic patients should be followed up regularly with
repeated neurophysiological examinations since relapses are
unpredictable and oblige to start the treatment.
Some patients will not relapse after this first course,
whereas some others (with relapsing-remitting form) will
need additional treatment that should be individually tailored
to achieve the most cost-effective regimen.
If a patient does not respond to one of the first-line ther-
apies, switching to another is advisable.
PE or a combination of steroids and IVIg can be started if
neither of these treatments proves effective. Refractory cases
may need intensive immunosuppression, according to the
general principle in medicine of escalating treatment for
severe disease [57].
Long-term maintenance therapy will require careful
attention because of side effects of treatments on the one hand
and because of the risk of relapse and axonal loss on the
other. Randomized clinical trials (RCT) with azathioprine,
methotrexate, or other immunosuppressive agents could not
provide evidence for their use as steroid or IVIg-sparing
treatments, but none of these trials was large enough to rule
out a small or moderate benefit.
3.1. Scores for Clinical Evaluation. CIDP diagnosis should be
as accurate as possible in agreement with EFNS 2010 guide-
lines [1]. Such criteria are quite accurate and provide a better
sensitivity compared to restrictive AAN criteria [68].
Patients with very mild symptoms, not or only slightly
interfering with activities of daily living, may be monitored
on a yearly basis by clinical examination, nerve conduction
studies, and electromyography (EMG); in selected cases,
when the diagnosis is not ascertained, sural nerve biopsy
might be performed.
To evaluate disability progression, several scales have
been proposed. In our opinion the Rankin Score, originally
proposed for stroke patients andmodified in 1988, lacks sensi-
tivity to detect mild improvement occurring in the treatment
of immune-mediated polyneuropathies [69]. Therefore, to
monitor disability in the follow-up setting, the INCAT
Overall Disability Sum Score (ODSS) should be preferred
[70].This score covers not onlymobility disturbances but also
upper limb dysfunction. Moreover, it has good clinimetric
properties; it captures a high proportion of variance of
disability and shows a good correlation with patients’ per-
ceptions [71, 72]. A recent report suggested that the Rasch-
built Overall Disability Scale, a scale that specifically captures
activity and social participation limitations in patients with
autoimmune demyelinating polyneuropathies, might detect
ability levels better than INCAT score [73]. Other authors
suggest separating the screening for motor and sensory def-
icits when evaluating CIDP patients, as only the motor scores
correlate with CIDP disease activity status (CDAS) [74]. The
CDAS is a classification focused on the long-term evolution
of CIDP [75].
For muscular strength evaluation, the Medical Research
Council (MRC) sum score is historically used [76], even
though a recent and large study conducted on patients with
neuromuscular diseases underlined possible limitations of
this score and proposed a simplified and probably more reli-
able version, referring to only four response categories [77].
On the other side, as a pure sensory score, the INCAT
Sensory Sum Score (ISS) has been proposed more than ten
years ago [78]. In our experience, distal sensory deficits, with
or without neuropathic pain, often persist even in aggres-
sively treated CIDP patients. This is probably due to irrevers-
ible axonal loss, but it rarely contributes to functional dis-
ability. The strong correlation between motor scores and the
disability scales could be explained by the fact that disability
is mainly due to the motor impairment: patients could refer
to increasing tingling and numbness without a change in the
INCAT score.
Finally, the small fibres damage cannot be measured with
standard EMG techniques, but it could be quantified in clini-
cal trials or research setting with quantitative sensory testing
(QST) and laser evoked potentials.
3.2. Newly Diagnosed Patients: First-Line Treatments. Treat-
ment with corticosteroids or IVIg should be offered to
patients with moderate or severe disability [1].
The efficacy of steroids in CIDP in the short term has
been repeatedly proved, first compared to placebo [79, 80]
and then to IVIg: in 2001 a controlled study has shown that
a 6-week course of 60mg daily oral prednisolone with rapid
tapering is as effective as one course of IVIg at 2 g/kg [81].
If there is no major contraindication (such as diabetes
or prediabetic stages as impaired fasting glucose or impaired
glucose tolerance) and since it is not possible to predict if
the patient will be steroid responder or not, we prefer to try
steroids first because of the need of a spending review [82]
and because long-term remission can be achieved in about
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one-quarter of patients with CIDP after 1 or 2 courses of
pulsed dexamethasone or 8-month daily prednisolone [83].
Intravenous or oral methylprednisolone [84], oral pred-
nisolone [81], and intravenous dexamethasone [85] are all val-
idated treatments.
However, as in other autoimmune disorders, long-term
steroids as monotherapy are usually not recommended
because of side effects (Cushing’s syndrome, cataracts, glau-
coma, diabetes, hypertension, weight gain, osteonecrosis,
gastrointestinal ulcer, psychiatric disturbances, peripheral
edema, hypokalemia, myopathy, and increased risk of infec-
tions).
According to literature, there is no consensus about
whether to use daily or alternate-day prednisolone or pred-
nisone or intermittent high-dosemonthly intravenous or oral
regimens. The generally accepted dosage for prednisolone is
60mg/day (1-1.5mg/kg) as induction therapy up to 12 weeks;
if there is a response, the dose should be tapered to a low
maintenance level over 1 or 2 years and eventually corticos-
teroids can bewithdrawn [1]. Both daily dosing and alternate-
day dosing for the oral treatment have been employed [86].
However, to our knowledge, if corticosteroids are chosen as
first-line treatment intravenous pulsed therapy seems to be a
more appropriate choice: the PREDICT study [85] could not
show a significant difference in terms of duration of remission
between pulsed high-dose dexamethasone and oral pred-
nisolone for 6 months, but the intravenous treatment led to a
faster improvement, relatively fewer relapses, and less adverse
events.
Our favourite first-line therapy is methylprednisolone
500mg IV for 4 consecutive days in the morning, every
month for 6 months, but the efficacy in the short term should
be equivalent to dexamethasone and prednisolone. Once IV
pulsed steroid treatment shows clear cut improvement (clini-
cal and on nerve conduction studies), an immunosuppressive
agent, such as azathioprine, can be introduced in addition to
oral maintenance therapy with prednisolone or prednisone at
a dose of 60–80mg/day until major improvement is seen.
Subsequently, oral steroids can be tapered, but if the
patient in remission experiences a relapse, one may consider
repeating the course of corticosteroids, especially if the first
course led to a long-term sustained remission.
As second-line treatments two opposite approaches could
be used and have equivalent effects: PE and IVIg [60].
If a patient does not respond to one of these first-line
therapies, it is advisable to switch to the other one [87], but
it is never clinically advisable to perform PE few days after an
IVIg course.
PE leads to rapid improvement in disability, clinical
impairment, and motor nerve conduction velocity in CIDP
[88]; however, the main limitations of PE are the short-
term benefit (usually 2 weeks) and the rate of side effects
related to difficulty with venous access, use of citrate, and hae-
modynamic changes [89].
Repeated treatments are usually required. The optimal
number of plasma exchange treatments has been reported for
the acute form GBS: in one large multicenter study [90] it
was shown that 2 PE are optimal for mild GBS, whereas 4 PE
should be reserved for patients with moderate/severe forms.
Polyclonal human immune globulin infusion is a highly
effective treatment based on multiple and still unknown
mechanisms of action [43], but its cost is comparable or lower
than that of PE [91] and it has fewer side effects compared to
PE. The maximal clinical response to IVIg should be evident
after 2 weeks from the infusion [92]. The therapeutic benefit
of IVIg in CIDP in the short term was evaluated by few
RCT in the 90s [93–95]. The benefit was greater for acutely
relapsing patients and was reproducible after subsequent
infusions [96].
In 2001 another RCT focused on 30 na¨ıve patients and
showed that IVIg is also effective as initial treatment [97].
Plasma exchange and IVIg are equally efficacious in the
short term inCIDPpatients [98], but PE ismuch less practical
for maintenance treatments.
The short term efficacy of IVIg compared to placebo is
supported by a large clinical trial on 117 CIDP patients called
the ICE study. More than 50% of patients treated with IVIg
had an improvement in the INCAT score, compared to only
20% of placebo-treated patients [55]. After this trial the use of
IVIg spread over and neurologists had to consider the option
of IVIg as a starting treatment [99].
The efficacy of IVIg in CIDP has been confirmed by a
Cochrane review: IVIg improves disability for at least two to
six weeks compared with placebo, with a number needed to
treat of 3 and efficacy similar to PE or oral prednisolone [100].
In our opinion IVIg is a first-line treatment in CIDP
patients with a proven contraindication to steroids and a sec-
ond-line treatment or add-on treatment in patients who do
not reach the expected improvement with steroids. We also
prefer IVIg treatment from the beginning in patients with
pure motor CIDP for whom a possible clinical worsening
under steroids has been reported in a small patients series
[67].
The switch from steroids to IVIg has to be considered if
the patient is developing severe side effects (diabetes, osteope-
nia or osteonecrosis, Cushing, or cataract), if the patient is
pregnant or wants to become pregnant, or if the patient is
worsening more quickly than expected.
The standard dose for starting IVIg is 0.4 g/kg for 5 days
(totally 2 g/kg) after checking IgA serum concentrations.The
first dose is fractionated to reduce the risk of possible side
effects or intolerance. Some side effects are correlated with
the speed of administration; the patient should be monitored
for headache, sweating, thoracic discomfort, and the dose
administered over a longer time of infusion (4-5 hours).
The maximal clinical response to IVIg should be evident
after 3 weeks from infusion [92]. It is advisable to schedule a
follow-up visit in an outpatient setting after 1 month and after
2 months from the beginning of treatment. The second infu-
sion of IVIg could be administered after an interval of 6weeks
from the previous infusion and during the second consult
the neurologist should establish a schedule for maintenance
infusions. Our standard maintenance dose is 0.5 g/day for
2 consecutive days (1 g/kg/month); a different dose should
be carefully evaluated by the neurologist, according to the
principle of the “lowest effective maintenance dose” [101].
Follow-up visits on a regular basis (every 4–6 months) may
help to decide if the IVIg dose should be modified.
6 Autoimmune Diseases
Combined treatment of steroids and IVIg from the begin-
ning is used in other severe autoimmune diseases (e.g., myas-
thenia gravis), but this has to be considered an off-label strat-
egy.
For patients with acute onset CIDP or with a severe form
of CIDP from the beginning (INCAT score of 3 or more)
we prefer treatment with IVIg or plasma exchange (with 5-6
exchanges of 1-1.5 plasma volumes over 10 days) plus steroids
and an immunosuppressive agent until major improvement
is noted.
3.3. Patients Already in Follow-Up. We always reconsider the
diagnosis of CIDP if the patient does not respond to first-
line treatment and in any case before starting an immunosup-
pressive drug, especially when there could be an underlying
paraproteinemic polyneuropathy. In case of disease progres-
sion despite treatment, sural biopsy [17, 102] and repeated
EMG studies could help to differentiate CIDP from other
polyneuropathies from other forms.
The combination of the INCAT score plus neurophysio-
logical follow-up could help to objectify the clinical improve-
ment. A definition of “responder” based on disability has
been suggested by Cocito and coauthors in a retrospective
observational analysis [25]: responders were those patients
who had an improvement of at least one point in the Rankin
Scale after therapy. About 70% of patients responded to first-
line immunological therapies: 61% to steroids, 73% to IVIg.
Lack of response to one treatment did not preclude a response
to another treatment: about 50% of the nonresponders to
first-line therapy became responders when switched to an
alternative drug, so that after a single switch the percentage of
responders reached 80% and this proportion could be higher
if treatments are combined.
Long-term treatment with corticosteroids has proved to
be effective [103] but is hampered by the development of side
effects that often cannot be adequately captured in short-term
trials, even those with one-year follow-up. To reduce side
effects, regimens alternatives to the standard 12 weeks oral
prednisolone followed by 1-2 years with slow tapering have
been suggested in the PREDICT study [85].
Recently, the long-term follow-up of the PREDICT study
[83] provided evidence that 1-2 courses of pulsed IV dexam-
ethasone or 8-month daily oral prednisolone allowed cure or
remission in 25% of 39 CIDP patients followedup for more
than 4 years.
During the monitoring period, the clinician should pre-
vent steroid-related side effects: every patient should be pro-
vided with calcium, vitamin D, and proton-pump inhibitors.
A careful monitoring of blood pressure, weight, blood sugar,
and osteopenia is mandatory in all patients treated with
steroids for more than 3 months.
The efficacy of long-term treatment with IVIg has been
investigated in retrospective studies in comparison to PE
[104] or to other treatment options in smaller [105] or larger
series [25].
11 CIDP patients treated for one year with IVIg were eval-
uated in a neurophysiological study that showed a decrease in
the rate of conduction blocks and axonal loss [106].Themost
reliable and consistent data about long-term efficacy and
safety of IVIg treatment come from the extension phase of the
ICE study [55]: relapse rate was significantly lower in IVIg-
treated patients compared to patients who received placebo,
with a side effects rate comparable between the two arms.
Periodic IVIg administration significantly sustained the ini-
tial improvement seen in CIDP patients and this effect could
last months without reinfusions in a significant proportion of
patients. In fact, 55% of patients rerandomized to placebo did
not relapse after 24 more weeks.
A recent retrospective study [107] focused on the long-
term effect of IVIg in 87 Spanish patients evaluated aftermore
than 48 weeks, with or without concomitant immunosup-
pressive medication. The dose of IVIg was individualized for
each patient, whereas doses and frequencies were fixed in the
ICE trial. The main finding of this study is that about one-
quarter of patients were stable at least 6 months after the
last IVIg infusion, suggesting that in the long term a careful
reevaluation of the patient conditions is mandatory to avoid
overtreatment and reduce costs for the healthcare system:
the optimal frequency and dose of IVIg infusion should be
individualized according to the patient’s need and disease
course, as also stated in the EFNS guidelines [1].
Since the costs of this therapy are very high, the neurol-
ogist should find the lowest effective maintenance dose. In
patients treated for years a temporary withdrawal could also
be attempted: this observation time could help to decide if the
patient has still, after years, a real benefit from the treatment,
because patients may need less IVIg than they receive or in
fact none at all. In an international study the IVIg dose could
be reduced by over 20% without deterioration in almost half
of the patients [108].
Some preliminary reports suggest that subcutaneous
immunoglobulin may be as effective as IVIg in the mainte-
nance therapy of CIDP [109, 110].
In 2012 IVIg and IV methylprednisolone (MP) treat-
ments were directly compared in a multicenter, randomized,
double-blind, placebo-controlled, parallel-group study [111].
This study provided evidence that the efficacy of MP is com-
parable to IVIg, but there are some differences concerning
tolerability and effect duration.A chronic treatmentwith ster-
oids is associatedwith a higher rate of side effects but alsowith
longer neurological stability. Overall, almost 50% of patient
from both groups did not require any further infusion after
one year since they showed either improvement or symptoms
stability.
Nonetheless, it should be noted that those results cannot
be translated to drug na¨ıve patients, since this study included
previously treated patients.
To sustain long-term remissions there is a need for “IVIg-
sparing” agents [112], as IVIg infusions are required every
3–6 weeks. In CIDP, immunosuppressive drugs such as aza-
thioprine, cyclosporine, methotrexate, mycophenolate, and
cyclophosphamide are generally used [113], but a Cochrane
meta-analysis concluded that there is no evidence that they
are effective [114].
Many years ago an open-label, randomized, controlled
trial [115] of 27 patients, comparing azathioprine in combi
nation with prednisone to prednisone, alone showed no
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significant difference between treatments, although it should
be noted that the sample size was small, the patient sample
was extremely heterogeneous, and the treatment period of
9 months was too short to draw conclusions about efficacy,
since several months have to pass before azathioprine reaches
maximal effect.
Despite this RCT, azathioprine has been widely used in
open label after initial PE or IVIg and corticosteroid treat-
ment to maintain remission.
In patients with a long history of disease or in patients
refractory to other treatments we start azathioprine at the
standard dose of 2-3mg/kg/day. This option seems to be
desirable also for patients preferring a home therapy instead
of a periodic access to the Day Hospital.
Data from a retrospective Italian study [116] suggest that
about 25% of patients refractory to first-line treatment do
respond to immunosuppressive agents (usually azathioprine
ormethotrexate formild forms, cyclophosphamide for severe
forms).
Oral methotrexate as a monotherapy in patients with
CIDP has been compared to placebo in an RCT [108] in 60
CIDP patients who had previously responded to and were
still receiving corticosteroids or IVIg. With a dose of 15mg
per week authors could not detect significant benefits, but
limitations in the trial design and the high rate of responses
in the placebo group meant that a treatment effect could not
be excluded.
The larger study regarding cyclosporin A efficacy is based
on a retrospective analysis of 19 Australian patients resistant
to other therapies [117]; the efficacy of this drug is counter-
balanced by kidney failure, an important side-effect.
There are few reports on the use ofmycophenolatemofetil
in CIDP in small series of patients with conflicting results
[118–120].
Two small series of 15 [121] and 5 patients [122] treated
with IV pulsed cyclophosphamide gave beneficial results, but
the toxicity of this drug limits its use to refractory cases.
According to uncontrolled studies [123–125] Rituximab
might be helpful in CIDP associated with hematological
disorders such as monoclonal gammopathy of undetermined
significance and multiple myeloma, but a very recent RCT
[126] on 54 patients with anti-MAG followed up for one year
has shownno significant benefit fromRituximab compared to
placebo in terms of changes in the ISS score [78]. Rituximab
also failed as an IVIg-sparing agent in patients dependent on
IVIg [127].
Retrospective analysis based on large population studies
shows that a certain proportion of CIDP patients remain
free of disease in the long term, regardless of their treatment
regimens; whether disease activity cessation was due to
treatment effect or to spontaneous remission of the disease
remains unknown [75, 107].
4. Conclusions
CIDP is a rare but treatable disease. Clinical experience indi-
cates that about 70%of patients will respond to immunomod-
ulation; there are patients responding to steroids, whereas
others, especially with pure motor CIDP, will benefit more
from IVIg or PE. It is becoming evident that CIDP is not a
uniform disease but includes several variants which might
have different response profiles.
First-line treatment choice depends on several factors,
such as disease severity, the presence of a pure motor form of
CIDP, contraindications and side effects of long-term therapy,
costs, and local availability of PE or IVIg.
We would encourage international guidelines specifically
devoted to define an algorithm for first-line therapy and for
standardized follow-up.
There is a need to improve the identification of CIDP sub-
formsnot only in terms of clinical presentation (typical versus
atypical) but also therapeutic response [75], especially for
the IVIg treatment. It is currently under debate whether the
profile of IVIg is favourable enough to outweigh the higher
costs associated with its long-term use.
In conclusion, as it is mandatory to avoid overtreatment
in benign forms, it is crucial to achieve long-term remission
in severe forms. A short-term intensive treatment may help
prevent prolonged use of corticosteroids or IVIg. In our expe-
rience, immunosuppressive agents are helpful in this long-
term strategy even if, until further controlled clinical trials
are available, they will remain off-label strategies.
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